Oncoprotein c-erbB-2 in squamous cell carcinoma of the uterine cervix and evaluation of its significance in response of disease to treatment.
Indian J Physiol Pharmacol
;
2001 Apr; 45(2): 191-8
Artigo
em Inglês
| IMSEAR
| ID: sea-107838
ABSTRACT
Tissues from 50 cases of squamous cell carcinoma of the uterine cervix were analysed for immunohistochemical expression of c-erbB-2 oncoprotein and the patients were followed-up for 2 years. Immunopositivity of c-erbB-2 was studied with reference to clinical stage, histopathological differentiation and response to the cancer therapy. Expression of c-erbB-2 protein was found to be higher (37.5%) in cases with stage II disease, whereas more expressions were noticed in poorly differentiated squamous cell carcinoma (33.3%). Among cases who showed complete response to the treatment, 20.8% were positive for c-erbB-2 oncoprotein. On the contrary, 36.8% of prognostically unfavourable cases revealed positivity for c-erbB-2 immunostaining. However, the difference between c-erbB-2 expressions of these two said groups of patients, which were divided in accordance with the response to treatment, did not attain to statistical significance. Study on c-erbB-2 among larger number of patients with cervical carcinoma may prove to be an important factor in response to cancer therapy.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Feminino
/
Humanos
/
Imuno-Histoquímica
/
Carcinoma de Células Escamosas
/
Neoplasias do Colo do Útero
/
Receptor ErbB-2
/
Adulto
/
Pessoa de Meia-Idade
Tipo de estudo:
Estudo prognóstico
Idioma:
Inglês
Revista:
Indian J Physiol Pharmacol
Ano de publicação:
2001
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS